US 12,281,168 B2
Binding molecule specific for LIF and use thereof
Qinghao Liu, Beijing (CN); Jun Tao, Beijing (CN); Wenlai Zhou, Beijing (CN); Shanshan He, Beijing (CN); Haiyan Yang, Beijing (CN); Hongling Wang, Beijing (CN); and Guiqun Yang, Beijing (CN)
Assigned to JACOBIO PHARMACEUTICALS CO., LTD., Beijing (CN)
Filed by JACOBIO PHARMACEUTICALS CO., LTD., Beijing (CN)
Filed on Aug. 20, 2021, as Appl. No. 17/407,264.
Application 17/407,264 is a continuation of application No. PCT/CN2020/118247, filed on Sep. 28, 2020.
Claims priority of application No. PCT/CN2019/108904 (WO), filed on Sep. 29, 2019; and application No. PCT/CN2020/077049 (WO), filed on Feb. 27, 2020.
Prior Publication US 2021/0403582 A1, Dec. 30, 2021
Int. Cl. C07K 16/24 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2866 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/94 (2013.01)] 9 Claims
 
1. An isolated anti-LIF (Leukemia Inhibitory Factor) monoclonal antibody or antigen-binding fragment thereof, comprising:
(a) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1;
(b) LCDR2 comprising the amino acid sequence of SEQ ID NO: 2;
(c) LCDR3 comprising the amino acid sequence of SEQ ID NO: 3;
(d) HCDR1 comprising the amino acid sequence of SEQ ID NO: 4;
(e) HCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and
(f) HCDR3 comprising the amino acid sequence of SEQ ID NO: 6.